Company intelligence / Profile preview

SpineThera

Plymouth, Minnesota, United States

Ownership: Private
Employees: ~8
Development stage: Phase 1

Overview

SX600 demonstrated clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection in a Phase 2 trial. The product aims to provide months-long sustained release of dexamethasone with best-in-class efficacy potential. There are currently no FDA-approved drugs for epidural injection to treat lumbar radicular pain. Market research indicates strong physician interest and high anticipated adoption rates if approved.

Therapeutic areas: NeurologyRheumatology
Modalities: Injectable drugsextended-release microspheres (dexamethasone acetate)micro-suspension technology
Industry: Biotech

Drug pipeline

1 asset

SX-600

Preclinical

Partnerships

ProMed Pharma LLC (manufacturing partnership; ProMed acquired manufacturing assets and will manufacture SX600 under contract)

Beyond the preview

Go deeper on SpineThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpineThera.

Explore the full profile